Lipid biomarkers, including common measures such as cholesterol and triglycerides as well as newer indicators like lipoproteins, apolipoproteins, and lipidomic profiles, are increasingly recognized as key drivers of cardiometabolic risk. Endocrine disorders such as diabetes, obesity, thyroid disease, adrenal disorders, and polycystic ovary syndrome are often linked to disruptions in lipid metabolism. These changes not only contribute to atherosclerosis, insulin resistance, and inflammation but also overlap with hormonal pathways that regulate metabolic balance. Recent progress in lab methods and systems-level research has provided deeper insights into how lipid biomarkers, endocrine function, and cardiometabolic outcomes interact. Understanding this connection is essential for improving risk assessment, uncovering mechanisms, and guiding more personalized treatment strategies in endocrinology.

This Research Topic aims to highlight new findings on how lipid biomarkers can be used to predict, monitor, and reduce cardiometabolic risk in the setting of endocrine disorders. By combining basic, clinical, and translational perspectives, we hope to uncover novel biomarkers, clarify their role in endocrine disease, and explore their potential as treatment targets. This collection also seeks to foster dialogue across endocrinology, cardiometabolism, and lipid research, with the goal of advancing both scientific understanding and patient care in endocrine-related metabolic dysfunction.

We welcome submissions addressing, but not limited to, the following areas:

• Identification and validation of lipid biomarkers in endocrine disorders (e.g., diabetes, obesity, thyroid and adrenal diseases, PCOS).

• Mechanistic links between lipid metabolism, hormonal signaling, and endocrine regulation.

• Roles of apolipoproteins, lipoprotein subfractions, and novel lipidomic profiles in cardiometabolic risk

• Clinical and translational studies on lipid biomarkers as predictors of cardiovascular events.

• Interventions (pharmacological, lifestyle, surgical, nutraceutical) modifying lipid profiles and outcomes.

• Multi-omics, systems biology, and precision medicine integrating lipid, endocrine, and metabolic pathways.

• Inflammation, oxidative stress, and vascular dysfunction as mediators of lipid-endocrine alterations.

Are you interested in contributing a manuscript to this Research Topic?

Lipid Biomarkers and Cardiometabolic Risk in Endocrine Disorders